Musashi-1 promotes stress-induced tumor progression through recruitment of AGO2

Hsiao-Yun Chen1,2, Mong-Lien Wang1,3,4, Benoit Laurent5

  • 1Division of Basic Research, Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan.

Theranostics
|January 7, 2020
PubMed

Insights

Stress causes Musashi-1 (MSI1) to move into the cytosol, where it binds AGO2, promoting tumor progression. Targeting MSI1 translocation and MSI1/AGO2 interaction offers a new therapeutic strategy for refractory cancers.

Area of Science:

  • Molecular biology
  • Oncology
  • Biochemistry

Background:

  • Carcinomatous progression and recurrence are significant challenges in treating refractory tumors.
  • The underlying molecular mechanisms driving these processes remain largely unknown.

Purpose of the Study:

  • To elucidate the molecular mechanisms of stress-induced tumor progression.
  • To identify novel therapeutic targets for refractory malignancies.

Main Methods:

  • Confocal microscopy and cell fractionation to observe MSI1 translocation.
  • Mass spectrometry and immunoprecipitation to identify MSI1 binding partners.
  • RNA-immunoprecipitation (RNA-IP) to map MSI1/AGO2 interactions with target mRNAs.
  • Overexpression of MSI1 C-terminus to disrupt MSI1/AGO2 interaction.

Main Results:

  • Elevated cytosolic Musashi-1 (MSI1) in malignant tumors, translocating under stress to promote progression.
  • Cytosolic MSI1 forms a complex with Argonaute 2 (AGO2), stabilizing or destabilizing target mRNAs.
  • MSI1 translocation and MSI1/AGO2 binding are critical for tumor progression; blocking them, including via MSI1 C-terminus overexpression, attenuates tumor growth.

Conclusions:

  • MSI1 plays a novel role in stress-induced cancer recurrence.
  • Targeting MSI1 translocation and its interaction with AGO proteins presents a promising therapeutic strategy for refractory cancers.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.8K